04280AAC4
Arrowhead Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A developer of RNA-interference medicines that silence disease-causing genes, Arrowhead's first FDA-approved drug, REDEMPLO, treats a rare condition called familial chylomicronemia syndrome by lowering triglycerides. The company began in 1989 as Arrowhead Research Corporation, a tech incubator that commercialized university patents, before pivoting to gene-silencing medicines after buying Roche's RNAi assets in 2011. Its name was chosen to symbolize a focused, forward-moving direction.
CONVERTIBLEUnderlying: ARWRCUSIP: 04280AAC4HealthcareUS1 derivative reporter
Convertible Senior Notes due 2032 (0%)
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
